undefined undefined
NaN.000
NaN.00%
Galectin Therapeutics press release (NASDAQ:GALT): Q1 GAAP EPS of -$0.19. As of March 31, 2024, the company had $23.6 million of cash and cash equivalents. The company believes it has sufficient cash ...
05-15 20:50
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
04-10 00:10
Madrigal Pharmaceuticals (NASDAQ:MDGL) said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network. Rezdiffra, also known as resmetirom, re...
04-09 22:03
Gainers: Longeveron (LGVN) +66%. Titan Pharmaceuticals (TTNP) +23%. MSP Recovery (LIFW) +19%. Outset Medical (OM) +16%. Palatin Technologies (PTN) +11%. Losers: Zhongchao (ZCMD) -11%. Adial Pharmaceut...
04-08 22:00
国际咨询公司Research Nester称,到2035年,全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。
03-18 09:00
Galectin Therapeutics (NASDAQ:GALT) reported its Q3 earnings results on Monday,...
2023-11-13 21:50
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global ...
2023-09-11 20:00
What is the target price for Galectin Therapeutics (GALT)?The latest price targ...
2023-08-15 19:16
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 28.57 percent. This is a 6.25 percent increase over losses of $(0.16) per share
2023-08-14 20:21
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Monday. The Dow traded up 0.50% to 35,404.68 while the NASDAQ rose 0.07% to 14,043.11. The S&P 500, also rose, gaining, 0.33% to 4,551.17.
2023-07-25 03:47